Assessment of tissue factor pathway inhibitor 2 (TFPI2) as a novel serum marker for malignant tumors of the ovary before and after treatment: A case‐control study

• DOI: 10.1111/jog.16241
• Publication Date: 2025-02-20T01:59:31Z
• Authors: Yuki Ogawara; Naho Ruiz Yokota; Yuki Yamada; Noriaki Arakawa; Kentaro Sakamaki; Hiroshi Kobayashi; Kazumi Kubota; Fuminori Kimura; Taichi Mizushima; Etsuko Yamazaki; Etsuko Miyagi

Abstract Aim Tissue factor pathway inhibitor 2 (TFPI2) is a preoperative biomarker that was developed to discriminate ovarian benign tumors from cancer and covered by health insurance in Japan. The purpose of this study evaluate how the TFPI2 changes after treatment. Methods Serum levels (cut off 191 pg/mL) CA125 35 U/mL) before primary debulking surgery patients with malignant were evaluated among recurrent nonrecurrent cases, respectively. Results A total 46 cases analyzed, including 11 borderline tumors, 13 clear cell carcinomas, 15 serous 4 endometrioid 3 mucinous carcinomas. Among 37 without recurrence, mean (235.3 pg/mL, range: 78.3–607.7) (1125.5 U/mL, 6.2–6272.0) higher than cutoff values. minimum level decreased below (150.2 range 56.4–471.1) at months or more surgeries. postoperative exceeded out recurrence (29.7%); however, 8 patients. maximum 9 492.6 pg/mL 727.4 Moreover, one (421.5 pg/mL), different (2903.8 U/mL). Conclusions Our results suggest clinical validity as serum tumor marker for screening tumors.